tbuckley/cabot-search huggingface dataset:
P-Wave Duration and Dispersion Analysis: Methodological Considerations
Authors: Polychronis E. Dilaveris, John E. Gialafos
Journal: Circulation (2001)

To the Editor:With great interest, we have read the article of Fan and colleagues 1 on the effects of biatrial pacing in the prevention of postoperative atrial fibrillation after coronary artery bypass surgery.By measuring P-wave duration from 12-lead surface ECGs and calculating P-wave dispersion, they found that biatrial pacing resulted in a more significant reduction in P-wave dispersion when compared with single-site atrial pacing.Although these results are interesting, we believe that they should be considered cautiously because of the limited accuracy of electrocardiographic measurements performed manually on paper-printed ECGs obtained at a standard signal size and paper speed.Our research group has introduced P-wave dispersion as a simple electrocardiographic predictor of paroxysmal lone atrial fibrillation. 2Although acceptable intraobserver and interobserver errors in the measurement of P-wave duration in 12-lead ECGs have been reported, 2 well-known difficulties in defining P-wave onset and offset may restrict the accuracy and reproducibility of the measurements.To overcome some of these restrictions, we introduced a more advanced technology-assisted method that enables us to measure P-wave duration from digitally recorded and stored ECG data. 3A computer-based ECG system is used, which records all 12 ECG leads simultaneously at a sampling rate of 1200 Hz and with 12-bit analog-to-digital conversion. 3 A sufficient sampling rate and amplitude resolution are necessary for high-resolution ECG analysis.For each lead, the average complex is calculated, and P-wave duration is measured manually from the average complexes displayed on a high-resolution computer screen. 3 To compare the different methods for manual P-wave duration measurement in 12-lead ECGs, another study was conducted. 4 The conclusion reached was that manual measurement of P-wave duration in standard 12-lead ECGs is feasible and more stable and reliable when performed on the high-resolution screen of a digital ECG system than with more conventional methods involving paper-printed ECGs. 4 Therefore, manual measurement of P-wave duration performed on standard paper-printed ECGs is of limited accuracy.To achieve greater precision in measuring P-wave duration from 12-lead ECGs obtained and stored on paper, we believe that scanning and digitizing ECG signals from paper records using an optical scanner is a feasible and accurate alternative method.
Interventions That Increase Use of Adult Immunization and Cancer Screening Services
Authors: Erin G. Stone, Sally C. Morton, Marlies E. Hulscher, Margaret A. Maglione, Elizabeth A. Roth, Jeremy M. Grimshaw, Brian S. Mittman, Lisa V. Rubenstein, Laurence Z. Rubenstein, Paul G. Shekelle
Journal: Annals of Internal Medicine (2002)

Purpose: The relative effectiveness of the diverse approaches used to promote preventive care activities, such as cancer screening and adult immunization, is unknown. Despite many high-quality published studies, practices and policymakers attempting to improve preventive care have little definitive information on which to base decisions. Thus, we quantitatively assessed the relative effectiveness of previously studied approaches for improving adherence to adult immunization and cancer screening guidelines. Data Sources: MEDLINE, the Cochrane Effective Practice and Organization of Care Review Group register, previous systematic reviews, and the Medicare Health Care Quality Improvement Project database. Study Selection: Controlled clinical trials that assessed interventions to increase use of immunizations for influenza and pneumococcal pneumonia and screening for colon, breast, and cervical cancer in adults. Data Extraction: Two reviewers independently extracted data on characteristics and outcomes from unmasked articles. Intervention components to increase use of services were classified as reminder, feedback, education, financial incentive, legislative action, organizational change, or mass media campaign. Data Synthesis: Of 552 abstracts and articles, 108 met the inclusion criteria. To assess the effect of intervention components, meta-regression models were developed for immunizations and each cancer screening service by using 81 studies with a usual care or control group. The most potent intervention types involved organizational change (the adjusted odds ratios for increased use of services from organizational change ranged from 2.47 to 17.6). Organizational change interventions included the use of separate clinics devoted to prevention, use of a planned care visit for prevention, or designation of nonphysician staff to do specific prevention activities. The next most effective intervention components were patient financial incentives (adjusted odds ratios, 1.82 to 3.42) and patient reminders (adjusted odds ratios, 1.74 to 2.75); the adjusted odds ratios ranged from 1.29 to 1.53 for patient education and from 1.10 to 1.76 for feedback. Conclusions: Rates of adult immunization and cancer screening are most likely to improve when a health care organization supports performance of these activities through organizational changes in staffing and clinical procedures. Involving patients in self-management through patient financial incentives and reminders is also likely to positively affect performance.
Abstract 944: Translational implications of the 19q12 bladder cancer GWAS signal for aggressive bladder cancer
Authors: Yi-Ping Fu, Indu Kohaar, Lee Moore, Petra Lenz, Jonine D. Figueroa, Wei Tang, Patricia Porter-Gill, Stephen Chanock, Stephen M. Hewitt, Debra T. Silverman, Nathaniel Rothman, Ludmila Prokunina-Olsson
Journal: Cancer Research (2014)

Abstract Background: A genome-wide association study (GWAS) of bladder cancer identified a genetic marker rs8102137 within the 19q12 region as a novel susceptibility variant. This marker is located upstream of the CCNE1 gene, which encodes cyclin E, a cell cycle protein. Methods: Genetic fine mapping analysis of the CCNE1 region was performed using data from two bladder cancer GWAS, which included a total of 5,942 cases and 10,857 controls. Cyclin E protein expression was evaluated by immunohistochemistry analysis in 265 bladder tumors in relation to CCNE1 genetic variants and tumor characteristics. Functional effects of cyclin E over-expression were evaluated with cell cycle assays. Findings: The original GWAS marker rs8102137 represents a group of 47 linked SNPs (with r2≥0.7) associated with increased bladder cancer risk. From this group we selected a functional promoter variant rs7257330, which showed strong allele-specific binding of nuclear proteins in several cell lines. In both GWAS, rs7257330 was associated only with aggressive bladder cancer (muscle-invasive or high-grade non-muscle-invasive cancer), with a per-allele odds ratio (OR) =1.18 (95%CI=1.09-1.27, p=4.67×10-5). Cyclin E protein expression was increased in aggressive bladder tumors (p=0.013) and, independently, with each rs7257330-A risk allele (ptrend=0.024). Over-expression of recombinant cyclin E in cell lines caused significant acceleration of cell cycle. Conclusions: Molecular mechanisms linking the CCNE1 GWAS signal and aggressive bladder cancer risk are related to cyclin E over-expression and cell cycle regulation. In combination with other genetic and clinical markers, CCNE1 genetic variants may be translationally useful for early prediction of aggressive bladder cancer. Citation Format: Yi-Ping Fu, Indu Kohaar, Lee Moore, Petra Lenz, Jonine D. Figueroa, Wei Tang, Patricia Porter-Gill, Stephen Chanock, Stephen M. Hewitt, Debra T. Silverman, Nathaniel Rothman, NCI-GWAS Bladder Cancer Consortium, Ludmila Prokunina-Olsson. Translational implications of the 19q12 bladder cancer GWAS signal for aggressive bladder cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 944. doi:10.1158/1538-7445.AM2014-944
Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism
Authors: David Q. Shih, Markus Bussen, Ephraim Sehayek, Meenakshisundaram Ananthanarayanan, Benjamin L. Shneider, Frederick J. Suchy, Sarah Shefer, Jaya S. Bollileni, Frank J. Gonzalez, Jan L. Breslow, Markus Stoffel
Journal: Nature Genetics (2001)
Hoarseness and Laryngopharyngeal Reflux
Authors: P. Marco Fisichella
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
903. Group I Ribozymes and SMaRT™ as Trans-Splicing RNA Repair Therapies for β-Globin Mutations
Authors: Carol H. Miao, Qili Zhu, Ling Zhou, Stephanie Humblet-Baron, Datien Lin, Donald B. Kohn, Fabio Candotti, Hans D. Ochs, David J. Rawlings
Journal: Molecular Therapy (2004)
Medications That Prolong the QT IntervalMedications That Prolong the QT Interval
Authors: Mori J. Krantz, Bridget A. Martell, Julia H. Arnsten, Marc N. Gourevitch, John A. Gillespie, Cathryn M. Clary, Carol Cappuccio, Sana M. Al-Khatib, Nancy M.Allen LaPointe, Judith M. Kramer, Robert M. Califf
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nitric oxide for ARDS and severe hypoxemic respiratory failure: Causes of non-responding
Authors: Vasiliy Shtabnitskiy, Alexander Chuchalin
Journal: European Respiratory Journal (2013)

Introduction: Acute respiratory distress syndrome (ARDS) is characterized by severe hypoxemic respiratory failure, and often require invasive ventilation with high level of FiO2 and PEEP. Nitric oxide (NO) is one of the ways to improve oxygenation among ARDS patients. Rate of response varies between 40-70%, there is no clear explanation for this phenomena.  Aims and objectives: To find out predictors of NO oxygenation improvement.  Methods: We included 29 ARDS patient, on invasive ventilation, who required FiO2>60 and/or PEEP>10, all patient were given inhaled NO. Improvement of FiO2/PaO2 index for 20%, were taken as positive response. APACHE II scale, lung injure score were used to assess patient severity, PaO2/FiO2, shunt fraction, oxygen consumption oxygen delivery and level of system inflamation were assessed.  Results: 62 % of patients had positive response for NO therapy. Mean PaO2/FiO2 improvement was 64.0 (±39.7). Responders had better cardiac output (6.8±2.2 vs 4.9±0.7) p=0.006, there were not significant difference between PaO2/FiO2 ratio (107.9±34.5 vs 122.8±33.2) p=0.08) and systemic inflammatory response: C-reactive protein (170.2±83.6 vs 225.5±75.4 p=0.07). Mortality rate was 47%. Mortality was related to high APACHE II and lung injury score, and high levels of CRP. Response rate to NO was not related to mortality, patient severity, oxygen consumption and delivery.  Conclusion: Nitric oxide administration leads to improvement in oxygenation among part of ARDS patients. Patients with worse cardiac output shown lower response rate to nitric oxide, more severe respiratory failure and lower system inflammation is probably associated with better response rate to nitric oxide.
Abstract 1868: Clinical significance of cathepsin L and B expression in pediatric acute myeloid leukemia
Authors: Garima Pandey, Sameer Bakhshi, Ratnakar Singh, Shyam S. Chauhan
Journal: Cancer Research (2014)

Abstract Introduction: Cathepsin L and B are commonly expressed cysteine proteinases that play a major role in lysosomal bulk proteolysis, protein processing, matrix degradation, and tissue remodelling. In tumors there is deregulation of these proteases that interferes with these normal biological processes. In a pilot study done in our lab expression of cathepsin L and B were found to be significantly elevated in peripheral blood mononuclear cells (PBMCs) of pediatric AML patients. However the expression of these proteases in bone marrow aspirate, which represents almost true population of blasts, has never been studied before. Methods: Enzymatic activities of cathepsin L and B were assayed in PBMCs and bone marrow mononuclear cells (BMMCs) of AML patients and healthy controls. Further expression of these proteases and its inhibitor were confirmed by western blotting and real time assay. Cell cycle analysis in PBMCs and BMMCs of these patients was performed by flow cytometry using propidium iodide. Results: In the PBMCs of pediatric AML patients activity of cathepsin L and B was found to be significantly elevated as compared to healthy controls. Similarly, increased activity of cathepsin L and B was also observed in the BMMCs when compared with PBMCs of these patients. Furthermore, protein and mRNA expression also confirmed the increased level of these proteases in pediatric AML. The protein and mRNA expression of their endogenous inhibitor cystatin-C was found to be decreased in PBMCs and BMMCs of AML patients. Moreover, expression of these proteases correlated positively with the percentage of blasts and percentage of cells in S-phase. Conclusion: This study for the first time demonstrates the increased expression of cathepsin L and B in the BMMCs and PBMCs of pediatric AML patients, along with a positive correlation with percentage of blasts, thereby suggesting a potential role of these proteases in the severity of this disease. Citation Format: Garima Pandey, Sameer Bakhshi, Ratnakar Singh, Shyam S. Chauhan. Clinical significance of cathepsin L and B expression in pediatric acute myeloid leukemia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1868. doi:10.1158/1538-7445.AM2014-1868
Repeat <sup>90</sup>Y-microsphere radioembolization for hepatic malignancies: Safety and patient selection issues
Authors: A. S. Kennedy, W. A. Dezarn, P. McNeillie, M. England, C. Overton, S. Sailer
Journal: Journal of Clinical Oncology (2007)

15177 Background: Liver tolerance to reirradiation with multiple doses of 90 Y-microspheres is not known. Many patients (pts) have also received external beam radiotherapy to the liver or through the liver and are surviving long enough to be considered for a second and third liver treatments with internal radiation. Methods: The experience of a single center treating liver tumors with resin 90 Y-microspheres was used. Pts that received liver radiation prior to or after resin microsphere therapy were studied. Endpoints were toxicity, tumor response, disease type, latency period between radiation treatments, shunting to lung, and effects on liver volume and function. The delivery activity of microspheres selected was not reduced below that which was typically chosen for patients without prior liver radiation which was 25% reduced from the manufacturer’s BSA dose calculation method. All patients received bilobar microsphere delivery during a single session. Results: A total of 40 pts were identified; 14 women, 26 men, treated 6/2003 to 12/2006, with 35 pts receiving 2 courses and 5 pts with 3 courses of liver radiation. Retreatment with resin microspheres 26 pts, prior external beam radiation in 7 pts, prior glass microspheres in 2pts, prior systemic radiotherapy in 2 pts, and prior stereotactic liver radiation in 1 pt. Liver function was stable and adequate in all patients after additional liver radiation, and no pts developed radiation-induced liver dysfunction (RILD) or veno-occlusive disease (VOD). The percentage of shunting to the lung decreased with retreatment. Tumors treated: 14 carcinoid, 11 colorectal, 6 hepatocellular and cholangiocarcinoma, 2 sarcoma, 3 unknown primary, 1 each of breast, esophagus, and head and neck primaries. Conclusions: Repeated radiation to the liver with 90 Y-microspheres appears safe in patients that have sufficient normal liver function and reserve based on known laboratory parameters already used for selection of microsphere therapy. No acute life-threatening, fatal, or late liver damage was observed, i.e. RILD or VOD. No specific dose reduction is recommended for retreatment of the liver. No significant financial relationships to disclose.
Nonsyndromic hearing impairment is associated with a mutation in DFNA5
Authors: Lut Van Laer, Egbert H. Huizing, Margriet Verstreken, Diederick van Zuijlen, Jan G. Wauters, Paul J. Bossuyt, Paul Van de Heyning, Wyman T. McGuirt, Richard J.H. Smith, Patrick J. Willems, P. Kevin Legan, Guy P. Richardson, Guy Van Camp
Journal: Nature Genetics (1998)
Abstract B90: Hapten enhanced personalized chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmuno-therapy: UMIPIC-therapy in advanced pancreatic cancer
Authors: Baofa Yu, Feng Gao, Wei Han, Zhenlu Ma
Journal: Cancer Research (2015)

Abstract Backgound: To evaluate the clinical effectiveness of hapten enhanced chemoimmunotherapy in the treatment of advanced pancreatic cancer by ultra-minimum incision personalized intratumoral chemoimmuno-Therapy (UMIPIC-Therapy) and to further analyze its role as an immune adjuvant. Method: Patients with late stage pancreatic cancer (92 cases) were treated with UMIPIC-Therapy or just intratumoral Chemotherapy (ITCT) , UMIPIC-Therapy is a proprietary therapeutic regimen which is composed of three components (i.e. an oxidant, a cytotoxic drug and a hapten) that is utilized in chemotherapeutic modulation. The patients (at end of study, 47 patients with complete response analysis data and 45 patients with complete survival data were in the randomly divided two groups: Control group of ITCT alone with an oxidant and a cytotoxic drug without hapten and the experimental group receiving UMIPIC-Therapy with an oxidant, a cytotoxic drug plus hapten. Result: In the ITCT (control) and UMIPIC (experimental) groups, the clinical response rates were 92.86% and 82.88% respectively; the median survival time and 6-month survival rate were 4.98 months vs 6.45 months and 45% vs 64%, respectively. While all of above mentioned showed no statistical difference (P&amp;gt;0.05), 1-year survival rate of the ITCT group was 5% while those of the ITCIT group was 28% and statistically significant (P&amp;lt;0.05). Conclusion: The hapten enhanced immunotherapy by ultra-minimum incision personalized intratuoral chemoimmuno-therapy (UMIPIC-Therapy) is shown to be effective in the pancreatic cancer. Our data suggests that the hapten plays an important role in prolonging the patient survival time is could be very valuable in future clinic applications. Citation Format: Baofa Yu, Feng Gao, Wei Han, Zhenlu Ma. Hapten enhanced personalized chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmuno-therapy: UMIPIC-therapy in advanced pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr B90.
Novel ultrasound-contrast-agent dilution method for assessment of left ventricular ejection faction
Authors: Ahm Annemieke Jansen, M Massimo Mischi, van Jm Jan Melle Dantzig, CH Peels, Fale Bracke, van Nm Hemel, Hhm Erik Korsten
Journal: Circulation (2006)

Background: Left ventricular ejection fraction (LVEF) is an important determinant of prognosis. We evaluated the accuracy of a novel fast method for LVEF quantification based on indicator dilution curve (IDC) principles (figure 1) and compared the results with contrast-enhanced biplane LVEF assessment. Method: a 10 ml diluted (1:100) ultrasound-contrast bolus (SonoVue ®) was injected intravenously in thirty patients (pts) (20 male, age 65 ± 10) with known or suspected heart disease. In 22 pts multiple recordings were made and in 12 pts injections were repeated after implantation of a biventricular pacemaker, leading to 68 measurements. The developed algorithm used the left atrium and LV IDC for the LVEF measurement. For the biplane enhanced LVEF measurements a 0.5 ml pure ultrasound-contrast bolus (SonoVue ®) was administered to obtain multiple four- and two-chamber recordings. Results: according to contrast enhanced biplane assessments, the LVEF ranged from 10 to 75 % while the LV end-diastolic volume ranged from 80 to 521 ml. The mean LVEF measured by the biplane and the IDC method was 33 ± 17 % and 35 ± 18 %, respectively. A correlation coefficient r=0.91 was observed between the two methods (figure 2). Conclusion: A new fast method for LVEF assessment based on IDC principles is described and comparison with contrast enhanced biplane LVEF quantification shows accurate results. The proposed method also allows simultaneous quantification of right ventricular EF based on the same IDC principles.